Search clinical trials for: MRD HSCT

Total 1089 results

Peking University People's Hospital
Ruijin Hospital; Wuhan TongJi Hospital; Anhui Provincial Hospital

Not yet recruiting

MRD Response-adapted Allo-HSCT for Adverse-risk AML

Acute Myeloid Leukemia
Peking University People's Hospital

Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute Leukemia | MDS | CML | MDS/MPN

China
Zhejiang University

Recruiting

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Acute Lymphoblastic Leukemia

China
Sheng-Li Xue, MD
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Hematopoietic Stem Cell Transplantation | ALL | MRD-positive

China
Karolinska University Hospital
Nordic MDS Group

Recruiting

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Myelodysplastic Syndromes | Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts | Mixed Myelodysplastic/Myeloproliferative Disease

Sweden
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Minimal Residual Disease | Bone Marrow Transplant | Ph+ ALL

China
National Research Center for Hematology, Russia
Federal Research Clinical Center of Federal Medical & Biological Agency,... and other collaborators

Recruiting

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

AML

Russian Federation
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic Malignancy | Stem Cell Transplant Complications

China
Novartis Pharmaceuticals

Recruiting

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Acute Myeloid Leukemia

Spain, Germany, Italy, France
National Cancer Institute (NCI)

Recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Federal Research Institute of Pediatric Hematology...
Physicians, Innovations, Science for Children Fund

Recruiting

A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Acute Myeloid Leukemia, Childhood

Russian Federation
Peking University People's Hospital

Recruiting

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Leukemia, Myeloid, Acute | Stem Cell Transplant Complications | Leukemia Relapse

China
Masonic Cancer Center, University of Minnesota

Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Lymphoma | Follicular Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous... and other conditions

United States
Prof. Christina Peters
Amgen

Terminated

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Minimal Residual Disease | ALL, Childhood

Norway, Spain, Denmark, Austria, Belgium, Czechia, France, Italy, Poland, Slovakia
University of Alabama at Birmingham
Miltenyi Biotec, Inc.

Active, not recruiting

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

Hematopoietic Stem Cell Transplantation

United States
Zhejiang University

Completed

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

Measurable Residual Disease

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Completed

MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion

China
Shenzhen Second People's Hospital

Unknown

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Lymphocytic, Acute, B-Cell

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Nanfang Hospital of Southern Medical University

Unknown

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Philadelphia Chromosome Positive Acute Lymphocytic Leukemia | Tyrosine Kinase Inhibitor

China
Nanfang Hospital of Southern Medical University

Unknown

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Leukemia | Lymphoblastic Lymphoma | Lymphoblastic Leukemia | Leukemia, Acute | Adult Lymphoblastic Lymphoma | Leukemia, Lymphoblastic | Leukemia, T Cell | Adult Acute Lymphoblastic Leukemia

China
Nanfang Hospital of Southern Medical University

Unknown

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Leukemia, Acute | Leukemia, Lymphoblastic | Leukemia, T Cell

China
Franco Locatelli
Fresenius AG; University of Milano Bicocca; medac GmbH

Unknown

T&B Depletion Non Malignant

Graft Versus Host Disease

Italy
Sun Yat-sen University

Not yet recruiting

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC (CONTINUE)

Lung Cancer, Nonsmall Cell
Sijia Gu

Not yet recruiting

Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT

Child, Only | Hematopoietic Stem Cell Transplantation | Graft-Versus-Host Disease | Haploidentical Hematopoietic Stem Cell Transplantation

China
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Exact Sciences Corporation
NSABP Foundation Inc

Not yet recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Breast Cancer
Exact Sciences Corporation
Labcorp Corporation of America Holdings, Inc

Recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer (MRD)

Colorectal Cancer

United Kingdom, Spain, Italy, Israel
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Leiden University Medical Center
Trombosestichting Nederland; ISTH

Recruiting

Optimizing Diagnosis of Splanchic Vein Thrombosis With MRDTI (Rhea)

Splanchnic Vein Thrombosis

Netherlands, Italy
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Refractory Acute Myeloid Leukemia | Conditioning | Hematopoietic Stem Cell Transplantation | Relapse Leukemia
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study

Acute Graft Versus Host Disease | Acute Kidney Injury | Stem Cell Transplant Complications | Major Adverse Cardiac Events
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
Siriraj Hospital

Not yet recruiting

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen (CMV)

CMV Infection or Reactivation After Allogenic HSCT
Anhui Provincial Hospital

Not yet recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

High Titers of Anti-HLA Antibody (MFI ≥5000)

China
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Shanghai Chest Hospital

Recruiting

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Carcinoma | Non-small Cell Lung Cancer

China
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT

Ocular Graft-versus-host Disease

Mexico
The First Hospital of Jilin University
Geneplus-Beijing Co. Ltd.

Recruiting

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

Endometrial Cancer

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Second Affiliated Hospital of Wenzhou Medical University

Recruiting

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Epithelial Ovarian Cancer

China
Wang Xin

Not yet recruiting

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

GVHD

China
Beijing GoBroad Hospital

Not yet recruiting

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia

China
Beijing GoBroad Hospital

Not yet recruiting

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Beijing GoBroad Hospital

Recruiting

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Leukemia

China
Cao Weijie

Recruiting

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Letemovir for the Prevention of CMV Infection After Allo-HSCT

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma

Search clinical trials for: MRD HSCT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations